Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average ...

Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Monday, February 17th. Leerink Partnrs analyst M. Goodman now ...